GALVmed’s commercial development activities are underwritten by the willingness of small-scale livestock producers (SSPs) to pay the market price for effective livestock health products (particularly vaccines) and services. It is this commercial principle that will allow GALVmed to achieve its ultimate vision of vaccines and other essential animal health products being widely available to SSPs around the globe.
The goals of GALVmed’s commercial development work are:
Under the Protecting Livestock Saving Human Lives I & II programmes, GALVmed conducted mainly small-scale pilot initiatives in market development designed to deliver certain products, predominantly Newcastle Disease (ND) vaccine for poultry and East Coast Fever (ECF) vaccine for cattle to small-scale producers in several African and South Asian countries. Having demonstrated economic viability of these field projects, larger market initiatives have now been developed with global and regional private sector manufacturers, distributors, SME’s and start-ups to achieve and sustain scale.
Currently, commercial development activities are focused on establishing large-scale distribution networks and providing a broad portfolio of animal health products to tackle economically important diseases for SSPs.
GALVmed’s commercial development function will continue to test and demonstrate the underlying business case for the establishment of distribution networks for the smallholder segment. With the animal health industry fully engaged in this way, hundreds of millions of SSPs around the world can have access to affordable and vitally needed agricultural inputs – livestock vaccines and medicines.